Clinical Remission of Rheumatoid Arthritis in a Multicenter Real-World Study in Asia-Pacific Region

Background: Clinical remission is an attainable goal for Rheumatoid Arthritis (RA). However, data on RA rates in Asia-Pacific region are lacking. We conducted a cross-sectional study to evaluate the clinical status and associated factors patients region. Methods: receiving standard care were enrolled consecutively from 17 sites 11 countries. Data collected on-site by rheumatologists with standardized case-report form. Remission was analyzed different definitions including disease activity score using 28 joints (DAS28) based ESR CRP, index (CDAI), simplified (SDAI), Boolean definition, deep (CliDR). Logistic regression used determine of remission. Findings: A total 2010 included study, overall 62·31% (DAS28-CRP), 35·51% (DAS28-ESR), 30·78% 26·50% 24·71% (Boolean), 17·06% (CliDR), respectively, varied Biological disease-modifying antirheumatic drugs (bDMARDs) prescription rate low (16·9%). Compared non-remission, had higher csDMARDs monotherapy, bDMARDs usage lower GC usage. The favorable male sex, younger age, fewer comorbidities, less extra-articular manifestations (EAM), use bDMARDs, while treatment negatively remission. Interpretation: region. Treatment related rate. There unmet need region. Funding Information: Beijing Municipal Science Technology Project (Z191100006619110), Key Laboratory Rheumatism Mechanism Immune Diagnosis (BZ0135), Peking-Tsinghua Center Life Sciences. Declaration Interests: None. Ethics Approval Statement: approved ethics committee each center.